Leukemia and Lymphoma | MyMerci
제안하기
0 / 2000

Leukemia and Lymphoma

Unit 7 · Topic 36Leukemia and Lymphoma
1.Overview & Pathophysiology

Hematologic cancers arise from blood-forming or immune cells. Nursing care centers on the consequences of bone marrow failure (infection, bleeding, anemia), the toxicity of treatment, and oncologic emergencies.

Leukemia — malignant white blood cell precursors multiply in the bone marrow, crowd out normal cells, and spill into the blood. Result: anemia (fatigue), neutropenia (infection — the leading cause of death), and thrombocytopenia (bleeding), even when the total WBC count is high.

TypeKey features
Acute myeloid leukemia (AML)Most common acute leukemia in adults; rapid onset. Acute promyelocytic leukemia (APL) is a subtype with a high risk of DIC and early bleeding death
Acute lymphoblastic leukemia (ALL)Most common childhood cancer; also occurs in adults. Tends to spread to the central nervous system (CNS) and testes
Chronic myeloid leukemia (CML)Philadelphia chromosome — translocation t(9;22) creating the BCR-ABL fusion gene; chronic phase can progress to blast crisis. Very high WBC, splenomegaly
Chronic lymphocytic leukemia (CLL)Most common leukemia in older adults in Western countries; slow; lymphocytosis, lymphadenopathy; often found on routine blood tests

Risk factors: ionizing radiation, benzene, prior chemotherapy, smoking (AML), Down syndrome and other genetic conditions.

Lymphoma — cancer of lymphocytes, usually beginning in lymph nodes.

  • Hodgkin lymphoma — Reed–Sternberg cells; painless enlarged lymph node (often cervical or supraclavicular) spreading to neighboring node groups in order; peaks in young adults and older adults; associated with Epstein–Barr virus; highly curable
  • Non-Hodgkin lymphoma (NHL) — a large, varied group; spreads unpredictably and often outside nodes. Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive type

Multiple myeloma — cancer of plasma cells in the marrow producing an abnormal monoclonal protein (M-protein). Plasma cells activate osteoclasts, causing lytic bone lesions. Remember CRAB: hyperCalcemia, Renal impairment, Anemia, Bone lesions.

2.Assessment Findings

Leukemia

  • Fatigue, pallor, dyspnea (anemia)
  • Fever and frequent infections (neutropenia)
  • Bleeding: petechiae, bruising, nosebleeds, gum bleeding (thrombocytopenia)
  • Bone pain, lymphadenopathy, splenomegaly, hepatomegaly
  • ALL: headache, vomiting, cranial nerve signs (CNS involvement)
  • CLL: often none at diagnosis

Lymphoma

  • Painless, rubbery lymph node enlargement
  • B symptoms: fever above 38 °C (100.4 °F), drenching night sweats, weight loss of more than 10% in 6 months
  • Pruritus (Hodgkin); cough or dyspnea from a mediastinal mass; superior vena cava obstruction (facial swelling, distended neck veins)

Multiple myeloma

  • Bone pain (back, ribs, pelvis) — the most common presenting symptom — and pathologic fractures
  • Hypercalcemia (confusion, thirst, constipation, polyuria), kidney injury, anemia, recurrent infections, spinal cord compression (back pain, leg weakness)
3.Diagnostics
TestKey finding
CBC with differential, peripheral smearCytopenias; blasts in acute leukemia; lymphocytosis in CLL; high WBC with all maturation stages in CML
Bone marrow aspiration and biopsyConfirms leukemia (acute leukemia usually ≥ 20% blasts), myeloma (clonal plasma cells), and marrow involvement by lymphoma
Flow cytometry, cytogenetics, molecular testsSubtype and prognosis; Philadelphia chromosome/BCR-ABL is specific for CML (also found in some ALL)
Excisional lymph node biopsyDiagnoses lymphoma (Reed–Sternberg cells in Hodgkin)
PET-CTLymphoma staging and response
Lumbar punctureCNS involvement (ALL, some lymphomas)
Serum/urine protein electrophoresis, serum free light chainsM-protein, Bence Jones protein in myeloma
Calcium, creatinine, uric acid, potassium, phosphate, LDHKidney function, tumor lysis risk, tumor burden
Coagulation studies (PT, aPTT, fibrinogen, D-dimer)DIC, especially in APL
4.Medical Management

Principles: combination chemotherapy in phases (induction → consolidation → maintenance for ALL), targeted drugs, immunotherapy, radiation, and hematopoietic stem cell transplant (HSCT).

DiseaseStandard approach
AMLIntensive induction chemotherapy, then consolidation or allogeneic HSCT; less-intensive regimens (e.g., venetoclax with azacitidine) for older or frail clients. Antifungal prophylaxis during induction
APLAll-trans retinoic acid (ATRA) plus arsenic trioxide — highly curable; treat coagulopathy urgently
ALLMultiphase chemotherapy; CNS prophylaxis with intrathecal chemotherapy (e.g., methotrexate); a tyrosine kinase inhibitor for Philadelphia-positive ALL; blinatumomab or CAR-T cell therapy for relapse
CMLOral tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib) — most clients achieve near-normal life expectancy
CLLWatchful waiting while asymptomatic and early stage; treat when symptomatic or progressive — BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) or venetoclax-based therapy
Hodgkin lymphomaABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) ± radiation; for advanced disease newer regimens replace bleomycin with brentuximab vedotin or nivolumab
DLBCLR-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or a similar rituximab-based regimen
Multiple myelomaCombinations such as daratumumab, bortezomib, lenalidomide, dexamethasone; autologous HSCT; bone-protecting agents

Drug safety

DrugKey toxicities and monitoring
DoxorubicinCardiotoxicity (cumulative dose) — baseline and follow-up echocardiogram; vesicant; red urine for 1–2 days
BleomycinPulmonary toxicity / fibrosis — baseline and serial pulmonary function tests; report cough or exertional dyspnea; caution with high oxygen concentrations
Vincristine, vinblastineVesicants; fatal if given intrathecally. Vincristine: peripheral neuropathy, constipation, paralytic ileus
CyclophosphamideHemorrhagic cystitis — hydration, frequent voiding, mesna with high doses
RituximabInfusion reactions (most common with the first infusion) — premedicate, start slowly, titrate. Screen for hepatitis B before starting (reactivation)
ATRA / arsenic trioxideDifferentiation syndrome (fever, dyspnea, pulmonary infiltrates, weight gain, hypotension) — report; treated with dexamethasone. Arsenic: QT prolongation — ECG, keep K⁺ and Mg²⁺ normal. Both teratogenic
Imatinib and other TKIsFluid retention, edema, muscle cramps, nausea, myelosuppression; dasatinib — pleural effusion; nilotinib — QT prolongation, take on an empty stomach
IbrutinibAtrial fibrillation, bleeding, hypertension
VenetoclaxTumor lysis syndrome — dose ramp-up, hydration, lab monitoring
BortezomibPeripheral neuropathy; herpes zoster reactivation (antiviral prophylaxis)
LenalidomideTeratogenic (restricted program); venous thromboembolism — thromboprophylaxis
Zoledronic acid / denosumabOsteonecrosis of the jaw (dental review before starting); zoledronic acid — kidney monitoring; denosumab — hypocalcemia
Filgrastim (G-CSF)Bone pain; rare splenic rupture (left upper quadrant or shoulder pain)
CAR-T cellsCytokine release syndrome (fever, hypotension, hypoxia) and neurotoxicity
5.Nursing Interventions

Listed in priority order.

  1. Febrile neutropenia is an emergency. Neutropenia: absolute neutrophil count (ANC) below 500/µL (0.5 × 10⁹/L), or expected to fall below 500 within 48 hours. Fever of 38.3 °C (101 °F) once or 38.0 °C (100.4 °F) sustained for 1 hour → obtain blood cultures and give broad-spectrum IV antibiotics within 60 minutes. Fever may be the only sign
  2. Infection prevention — hand hygiene is most important; private room when profoundly neutropenic; avoid sick visitors; no rectal temperatures, suppositories, or enemas; meticulous central line and mouth care; safe food handling
  3. Respiratory symptoms in prolonged neutropenia — fever with dyspnea and new lung infiltrates after AML chemotherapy suggests invasive fungal infection (e.g., aspergillosis); report immediately
  4. Infusion reactions — for flushing, dyspnea, or hypotension during rituximab, stop the infusion immediately, keep the IV line open, stay with the client, notify the provider, and give emergency medications per protocol
  5. Bleeding precautions (platelets below about 50,000/µL, strict below 20,000/µL) — soft toothbrush, electric razor, avoid IM injections and invasive procedures, no aspirin or NSAIDs, fall prevention; prophylactic platelet transfusion usually below 10,000/µL in stable clients (higher before procedures or with bleeding or fever)
  6. Tumor lysis syndrome — aggressive hydration, allopurinol or rasburicase (contraindicated in G6PD deficiency), strict intake and output, ECG monitoring. Watch for hyperkalemia, hyperphosphatemia, hypocalcemia (secondary to high phosphate), and hyperuricemia leading to acute kidney injury; do not add potassium to IV fluids; treat hypocalcemia only if symptomatic
  7. Myeloma care — encourage fluids (about 2–3 L/day unless restricted) to protect the kidneys; avoid NSAIDs and unnecessary contrast; careful handling and fall prevention; encourage safe weight-bearing activity; watch for hypercalcemia and spinal cord compression
  8. Chemotherapy safety — verify vesicant administration, check blood return, stop immediately for extravasation; safe handling of hazardous drugs; antiemetics before chemotherapy
  9. Psychosocial support, fatigue, nutrition, and fertility counseling before treatment
6.Client Education
  • Take temperature daily and whenever feeling unwell; report 38.0 °C (100.4 °F) or higher immediately — do not wait, and do not take fever-reducing drugs before calling (they can mask fever); avoid rectal thermometers and suppositories
  • Wash hands often; avoid crowds and people who are sick; ask about recommended inactivated vaccines — avoid live vaccines during treatment
  • Avoid aspirin and NSAIDs; use a soft toothbrush; report nosebleeds, gum bleeding, black stools, or blood in urine
  • Food safety: wash produce, cook meat and eggs thoroughly, avoid unpasteurized products
  • CML: take TKIs daily exactly as prescribed; do not stop on your own; report swelling or rapid weight gain
  • Report mouth sores, cough, shortness of breath, numbness or tingling, severe constipation
  • Lenalidomide and many chemotherapy drugs: use reliable contraception
  • Myeloma: drink fluids; report new back pain, leg weakness, or confusion
  • Follow-up is lifelong for late effects (heart, lungs, secondary cancers)
7.Complications & Red Flags
ComplicationWhat to watch for
Neutropenic sepsisFever, hypotension, tachycardia, altered mental status
Disseminated intravascular coagulation (APL)Oozing from sites, petechiae, low fibrinogen
Tumor lysis syndromeDysrhythmias, muscle cramps, oliguria, seizures
Invasive fungal pneumoniaFever, cough, dyspnea, hemoptysis, lung infiltrates
Leukostasis (very high WBC)Dyspnea, hypoxemia, confusion, visual changes
Spinal cord compression (myeloma, lymphoma)New back pain, leg weakness, bladder/bowel changes
Superior vena cava syndrome (mediastinal lymphoma)Facial and arm swelling, distended neck veins, dyspnea
Hypercalcemia (myeloma)Confusion, polyuria, constipation, shortened QT
8.High-Yield Points
  • Leukemia → anemia, infection, bleeding from marrow crowding
  • Febrile neutropenia: cultures and antibiotics within 60 minutes
  • CML = Philadelphia chromosome (BCR-ABL) → TKIs (imatinib)
  • CLL: asymptomatic early disease → watchful waiting
  • APL: DIC risk; treated with ATRA + arsenic trioxide; watch differentiation syndrome
  • ALL: CNS prophylaxis with intrathecal chemotherapy
  • Hodgkin: Reed–Sternberg cells, painless node, B symptoms; bleomycin → pulmonary fibrosis
  • DLBCL: R-CHOP; rituximab reaction → stop infusion immediately and notify
  • Doxorubicin → cardiotoxicity; vincristine → neuropathy; cyclophosphamide → hemorrhagic cystitis
  • Platelets very low → no aspirin/NSAIDs, bleeding precautions
  • Myeloma: CRAB; bone pain and pathologic fractures most common; hydrate
  • Prolonged neutropenia + fever + lung infiltrates → suspect aspergillosis

Country Notes

United States

  • Treatment often occurs in outpatient infusion centers; clients must know when and how to call the oncology team for fever after hours.
  • Restricted distribution programs (REMS) apply to lenalidomide and related drugs.

Philippines

  • Access to targeted drugs and transplant varies; many clients with CML obtain imatinib through patient-access or charity programs — teach adherence and warn against interrupting therapy.
  • Screen for hepatitis B before rituximab — hepatitis B is common in the Philippines — and screen for TB exposure before intensive immunosuppression.
  • Dengue causes fever with low platelets; in a client with leukemia, both must be considered.

다음 이론을 계속 학습하려면 로그인하세요.

로그인하고 계속 학습
컨텐츠를 그만볼래?

필기노트, 하이라이터, 메모는 잘 쓰고 있어?

내보내줘
어떤 폴더에 저장할래?

컨텐츠 노트에는 총 0개의 폴더가 있어!

폴더 만들기
컨텐츠 만들기
만들기
신고했어요.

운영진이 검토할게요!

해당 유저를 차단했어요.

마이페이지에서 차단한 회원을 관리할 수 있어요.